Navigation Links
Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections
Date:10/27/2008

Reinach, Switzerland, 26 October 2008 Arpida (SWX: ARPN) today presented the combined results from two pivotal Phase III clinical trials at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, DC. In these studies, intravenous iclaprim, a novel antibiotic, showed high clinical cure rates which were similar to those of the comparator drug, linezolid, in the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In addition, iclaprim was well-tolerated with a safety profile that compared favorably to linezolid. A New Drug Application for intravenous iclaprim in cSSSI will be discussed at the meeting of the U.S. Food and Drug Administration Anti-Infective Drugs Advisory Committee on 20 November 2008.

Iclaprim, a novel antibiotic from the trusted dihydrofolate reductase (DHFR) selective inhibitor class of antibiotics, was specifically designed to address the growing need for additional treatment options to combat resistant infections including MRSA. MRSA affects more than 2 million people in the United States each year and rates of hospital- and community-acquired MRSA are on the rise. ,

"The high efficacy rates and favorable tolerability profile of iclaprim strongly supports its potential as a new treatment option for patients who have acquired serious infections caused by MRSA," said Dennis L. Stevens, MD, PhD, Veterans Affairs Medical Center, Boise, Idaho. "With rates of MRSA increasing and effectiveness of some current antibiotics declining, it is important to identify effective alternative treatments for these infections."

The results presented at the ICAAC/IDSA meeting were gathered from the ASSIST-1 and ASSIST-2, (Arpida's Skin and Skin Structure Infection STudy) pivotal Phase III studies involving a total of 991
'/>"/>

Contact: Dr. Jrgen Raths
41-614-179-660
Zeno Group
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
2. Improved foam for varicose veins found to be safe in preliminary results from phase II trial
3. Moms obesity during conception phase may set the stage for offsprings obesity risk
4. Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth
5. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
6. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
7. CABI helps phase out dangerous pesticide in EU
8. SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
9. New test promises quicker, more accurate evaluation for cystic fibrosis patients
10. How eating fruit and vegetables can improve cancer patients response to chemotherapy
11. UCSF Fresno leading-edge study lends hope to emphysema patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
(Date:12/3/2014)... Dec. 2, 2014 As part of our ... Technologies is pleased to announce the release of a ... to collect the workforce data that they need. ... been left by existing readers. Many such devices have ... and modern technology. Older models force users to navigate ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... attaining a reliable water supply for California and ... realized until better planning can identify how trade-offs ... water is limited, says a new report from ... been ineffective in meeting these goals because management ...
... Research led by Lauren Cole, a public health graduate ... Health and Director of the Epidemiology Program at LSU ... of head and neck cancer has risen at sites ... greatest increase among middle-aged white men. At the same ...
... An international team of researchers led by the University ... discovery of a breast cancer risk gene and could assist ... Melissa Southey of the Genetic Epidemiology Laboratory, Department of Pathology ... it was a significant discovery and the first breast cancer ...
Cached Biology News:Increasing water scarcity in California's Bay-Delta will necessitate trade-offs; 'hard decisions' needed to balance various environmental risks 2Increasing water scarcity in California's Bay-Delta will necessitate trade-offs; 'hard decisions' needed to balance various environmental risks 3Increasing water scarcity in California's Bay-Delta will necessitate trade-offs; 'hard decisions' needed to balance various environmental risks 4LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men 2Breast cancer risk gene discovery fast tracked by new technology 2
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... Mass. , Dec. 19, 2014 Decision ... market will grow at a 12 percent compound annual ... result of the aging population and the increasing adoption ... Latin America will also spur demand for ... of dental implant and periodontal treatments. Other ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 Ed Bilsky, ... of the Center for Excellence in the Neurosciences (CEN), ... England, has been selected as a member of the ... the first neuroscientist from Maine to receive this honor. ... organization supported entirely by the Dana Foundation. Its ...
(Date:12/19/2014)... Diego, CA (PRWEB) December 18, 2014 ... a limited time special on Sartorius Biohit products ... Free on mLINE pipettes, Picus Electronic Pipette Trade-in Program, ... by Health and Safety officers around the world. They ... manual pipetting. Other features include:, ,     Full ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... P&G,s Commitment to Sustainable Innovation., Accelerates LS9,s Entry into ... ... South San Francisco, CA (PRWEB) -- LS9, Inc., the ... Procter and Gamble (NYSE: PG), one of world,s largest consumer ...
... goBalto.com , ... San Francisco, CA ... partnering site for the pharmaceutical development and drug manufacturing industry, ... of India-based Investigator Sites and hospitals available on goBalto.com. , ...
... Reprints NRx for the Force.com AppExchange saves time for ... process from within Salesforce CRMSANTA MONICA, Calif., May 19 ... announced the availability of Reprints NRx for ... the Force.com platform, Reprints NRx for the AppExchange is ...
Cached Biology Technology:LS9 and Procter & Gamble Launch Sustainable Chemicals Partnership 2goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites 2goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites 3Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 2Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 3
Ms anti-Cyclophilin D...
... to qualitatively detect EGFR ... paraffin-embedded (FFPE) tissue sections, ... cell preparations, using Chromogenic ... Fluorescent In Situ Hybridization ...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Biology Products: